2016年5月13日

Success Stories: EB-1A Petition Approved for Postdoctoral Scientist from India in the Field of Immunology


Client’s Testimonial:
“Thank you so much. I received the notice of I-140 approval today in the post. It got approved within a day of submission. Thank you very much for filing my case. I have already recommended 3 of my colleagues who are planning to file Green card to avail your services”

On February 4th, 2016, we received another EB-1A (Alien of Extraordinary Ability) approval for a Postdoctoral Scientist in the Field of Immunology (Approval Notice).

 
 
 
 
General Field: Immunology
Position at the Time of Case Filing: Postdoctoral Scientist
Country of Origin: India
Service Center: Texas Service Center (TSC)
State of Residence at the Time of Filing: Texas
Approval Notice Date: February 4th, 2016
Processing Time: 3 days (Premium Processing requested)


 
Case Summary:

Just three days after North America Immigration Law Group (WeGreened.com) filed an EB-1A (Alien of Extraordinary Ability) petition under Premium Processing, the USCIS sent us an approval notice. In this case, our client was an Indian postdoctoral scientist working in the field of immunology.
In addition to highlighting our client’s professional record—182 citations to his 9 publications—we also carefully accounted for his research on vaccines to prevent and treat many prevalent diseases, including HIV and leukemia. We established that our client’s work greatly advances the United States pharmaceutical and medical sectors. We also detailed our client’s Ph.D. in Life Sciences and the 21 reviews he conducted on behalf of several top-rated journals. To further strengthen our EB-1A petition, we encouraged our client to contact expert immunologists for recommendation letters. The six letters that he managed to obtain were included in our well-balanced petition dossier and submitted to the USCIS. One of the recommenders had this to say about our client’s work: “His work has resulted in the creation of compounds relevant to the treatment of cancer, the treatment of diabetes and obesity, birth control, and, of course, the treatment of HIV. Effective treatments for these prevalent issues will, without any doubt, continue to be produced by [Client] if he stays in the United States.”
This EB-1A approval is another encouraging example of our firm’s dedication to getting our clients one step closer to permanent residency. We wish our client the best in his continued studies, and we thank him for choosing us to represent his EB-1A case.